Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors

Paula Marincola Smith, Jordan Baechle, Marcus C. Tan, Carmen C. Solórzano, Alexandra G. Lopez-Aguiar, Mary Dillhoff, Eliza W. Beal, George Poultsides, John G.D. Cannon, Flavio G. Rocha, Angelena Crown, Clifford S. Cho, Megan Beems, Emily R. Winslow, Victoria R. Rendell, Bradley A. Krasnick, Ryan C. Fields, Shishir K. Maithel, Christina E. Bailey, Kamran Idrees

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Background: Insurance status predicts access to medical care in the USA. Previous studies have shown uninsured patients with some malignancies have worse outcomes than insured patients. The impact of insurance status on patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is unclear. Patients and Methods: A retrospective cohort study of adult patients with resected GEP-NETs was performed using the US Neuroendocrine Tumor Study Group (USNETSG) database (2000–2016). Demographic and clinical factors were compared by insurance status. Patients ≥ 65 years were excluded, as these patients are almost universally covered by Medicare. Kaplan–Meier and log-rank analyses were used for survival analysis. Logistic regression was used to assess factors associated with overall survival (OS). Results: The USNETSG database included 2022 patients. Of those, 1425 were aged 18–64 years at index operation and were included in our analysis. Uninsured patients were more likely to have an emergent operation (7.9% versus 2.5%, p = 0.01) and less likely to receive postoperative somatostatin analog therapy (1.6% versus 9.9%, p = 0.03). OS at 1, 5, and 10 years was significantly higher for insured patients (96.3%, 88.2%, and 73.8%, respectively) than uninsured patients (87.7%, 71.9%, and 44.0%, respectively) (p < 0.01). On Cox multivariate regression analysis controlling for T/M stage, tumor grade, ASA class, and income level, being uninsured was independently associated with worse OS [hazard ratio (HR) 2.69, 95% confidence interval (CI) 1.32–5.48, p = 0.006]. Conclusions: Insurance status is an independent predictor of survival in patients with GEP-NETs. Our study highlights the importance of access to medical care, disparities related to insurance status, and the need to mitigate these disparities.

Original languageEnglish
JournalAnnals of Surgical Oncology
DOIs
StateAccepted/In press - Jan 1 2020

Fingerprint Dive into the research topics of 'Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors'. Together they form a unique fingerprint.

  • Cite this

    Marincola Smith, P., Baechle, J., Tan, M. C., Solórzano, C. C., Lopez-Aguiar, A. G., Dillhoff, M., Beal, E. W., Poultsides, G., Cannon, J. G. D., Rocha, F. G., Crown, A., Cho, C. S., Beems, M., Winslow, E. R., Rendell, V. R., Krasnick, B. A., Fields, R. C., Maithel, S. K., Bailey, C. E., & Idrees, K. (Accepted/In press). Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-020-08359-z